annual cash & cash equivalents:
$966.43M+$153.74M(+18.92%)Summary
- As of today (August 25, 2025), ALNY annual cash & cash equivalents is $966.43 million, with the most recent change of +$153.74 million (+18.92%) on December 31, 2024.
- During the last 3 years, ALNY annual cash & cash equivalents has risen by +$146.45 million (+17.86%).
- ALNY annual cash & cash equivalents is now at all-time high.
Performance
ALNY Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$2.86B+$225.36M(+8.56%)Summary
- As of today (August 25, 2025), ALNY quarterly cash & cash equivalents is $2.86 billion, with the most recent change of +$225.36 million (+8.56%) on June 30, 2025.
- Over the past year, ALNY quarterly cash & cash equivalents has increased by +$232.94 million (+8.87%).
- ALNY quarterly cash & cash equivalents is now at all-time high.
Performance
ALNY quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ALNY Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +18.9% | +8.9% |
| 3 y3 years | +17.9% | +35.4% |
| 5 y5 years | +76.6% | +48.4% |
ALNY Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +18.9% | at high | +38.9% |
| 5 y | 5-year | at high | +94.6% | at high | +67.2% |
| alltime | all time | at high | +6144.3% | at high | >+9999.0% |
ALNY Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $2.86B(+8.6%) |
| Mar 2025 | - | $2.63B(-2.3%) |
| Dec 2024 | $966.43M(+18.9%) | $2.69B(-3.1%) |
| Sep 2024 | - | $2.78B(+5.9%) |
| Jun 2024 | - | $2.62B(+10.7%) |
| Mar 2024 | - | $2.37B(-2.8%) |
| Dec 2023 | $812.69M(-6.2%) | $2.44B(+1.4%) |
| Sep 2023 | - | $2.41B(+17.0%) |
| Jun 2023 | - | $2.06B(-0.6%) |
| Mar 2023 | - | $2.07B(-5.6%) |
| Dec 2022 | $866.39M(+5.7%) | $2.19B(-3.2%) |
| Sep 2022 | - | $2.27B(+7.3%) |
| Jun 2022 | - | $2.11B(-5.8%) |
| Mar 2022 | - | $2.24B(-8.1%) |
| Dec 2021 | $819.98M(+65.1%) | $2.44B(+4.7%) |
| Sep 2021 | - | $2.33B(+22.5%) |
| Jun 2021 | - | $1.90B(+11.1%) |
| Mar 2021 | - | $1.71B(-8.9%) |
| Dec 2020 | $496.58M(-9.2%) | $1.88B(+2.3%) |
| Sep 2020 | - | $1.83B(-4.8%) |
| Jun 2020 | - | $1.93B(+43.4%) |
| Mar 2020 | - | $1.34B(-12.6%) |
| Dec 2019 | $547.18M(+30.2%) | $1.54B(-10.7%) |
| Sep 2019 | - | $1.72B(-10.7%) |
| Jun 2019 | - | $1.93B(+54.8%) |
| Mar 2019 | - | $1.24B(+14.8%) |
| Dec 2018 | $420.15M(-34.9%) | $1.08B(-12.3%) |
| Sep 2018 | - | $1.24B(-14.6%) |
| Jun 2018 | - | $1.45B(-7.7%) |
| Mar 2018 | - | $1.57B(-7.3%) |
| Dec 2017 | $645.36M | $1.69B(+78.3%) |
| Sep 2017 | - | $948.29M(+2.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $923.27M(+65.0%) |
| Mar 2017 | - | $559.60M(-10.7%) |
| Dec 2016 | $193.62M(+7.0%) | $626.80M(-12.1%) |
| Sep 2016 | - | $713.14M(-16.7%) |
| Jun 2016 | - | $856.40M(-15.5%) |
| Mar 2016 | - | $1.01B(-6.2%) |
| Dec 2015 | $180.90M(+140.6%) | $1.08B(+6.3%) |
| Sep 2015 | - | $1.02B(+1.2%) |
| Jun 2015 | - | $1.00B(-5.8%) |
| Mar 2015 | - | $1.07B(+53.1%) |
| Dec 2014 | $75.18M(+41.4%) | $696.69M(+10.2%) |
| Sep 2014 | - | $631.93M(-3.5%) |
| Jun 2014 | - | $654.76M(-1.6%) |
| Mar 2014 | - | $665.49M(+170.7%) |
| Dec 2013 | $53.17M(+3.4%) | $245.87M(+26.9%) |
| Sep 2013 | - | $193.78M(-7.6%) |
| Jun 2013 | - | $209.69M(-11.2%) |
| Mar 2013 | - | $236.01M(+92.2%) |
| Dec 2012 | $51.41M(-26.8%) | $122.81M(-46.2%) |
| Sep 2012 | - | $228.34M(-0.3%) |
| Jun 2012 | - | $229.02M(+15.0%) |
| Mar 2012 | - | $199.09M(+806.4%) |
| Dec 2011 | $70.23M(-5.9%) | - |
| Dec 2010 | $74.60M(-45.7%) | - |
| Dec 2009 | $137.47M(-28.3%) | - |
| Dec 2008 | $191.79M(+82.4%) | - |
| Dec 2007 | $105.16M(-17.8%) | - |
| Dec 2006 | $127.95M(+712.1%) | - |
| Dec 2005 | $15.76M(-22.3%) | - |
| Dec 2004 | $20.27M(-12.6%) | - |
| Mar 2004 | - | $21.97M(-5.3%) |
| Dec 2003 | $23.19M(+49.9%) | $23.19M |
| Dec 2002 | $15.48M | - |
FAQ
- What is Alnylam Pharmaceuticals, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Alnylam Pharmaceuticals, Inc.?
- What is Alnylam Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
- What is Alnylam Pharmaceuticals, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Alnylam Pharmaceuticals, Inc.?
- What is Alnylam Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
What is Alnylam Pharmaceuticals, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of ALNY is $966.43M
What is the all time high annual cash & cash equivalents for Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. all-time high annual cash & cash equivalents is $966.43M
What is Alnylam Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, ALNY annual cash & cash equivalents has changed by +$153.74M (+18.92%)
What is Alnylam Pharmaceuticals, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of ALNY is $2.86B
What is the all time high quarterly cash & cash equivalents for Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. all-time high quarterly cash & cash equivalents is $2.86B
What is Alnylam Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, ALNY quarterly cash & cash equivalents has changed by +$232.94M (+8.87%)